Amneal [AMRX] vs Zoetis [ZTS] Detailed Stock Comparison
Amneal
NASDAQ
Loading...
Zoetis
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Amneal wins in 8 metrics, Zoetis wins in 11 metrics, with 0 ties. Zoetis appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Amneal | Zoetis | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 953.00 | 25.36 | Zoetis |
| Price-to-Book Ratio | -26.76 | 13.14 | Amneal |
| Debt-to-Equity Ratio | -22.94 | 137.01 | Amneal |
| PEG Ratio | 3.81 | 23.24 | Amneal |
| EV/EBITDA | 8.90 | 17.91 | Amneal |
| Profit Margin (TTM) | 0.12% | 27.83% | Zoetis |
| Operating Margin (TTM) | 15.46% | 40.20% | Zoetis |
| EBITDA Margin (TTM) | 15.46% | 40.20% | Zoetis |
| Return on Equity | 106.73% | 52.77% | Amneal |
| Return on Assets (TTM) | 6.85% | 15.37% | Zoetis |
| Free Cash Flow (TTM) | $220.11M | $2.30B | Zoetis |
| Dividend Yield | N/A | 1.11% | N/A |
| 1-Year Return | 14.44% | -13.42% | Amneal |
| Price-to-Sales Ratio (TTM) | 1.05 | 6.96 | Amneal |
| Enterprise Value | $5.57B | $70.67B | Zoetis |
| EV/Revenue Ratio | 1.95 | 7.53 | Amneal |
| Gross Profit Margin (TTM) | 39.51% | 73.62% | Zoetis |
| Revenue per Share (TTM) | $9 | $21 | Zoetis |
| Earnings per Share (Diluted) | $0.01 | $5.81 | Zoetis |
| Beta (Stock Volatility) | 1.12 | 0.88 | Zoetis |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Amneal vs Zoetis Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Amneal | 0.63% | 1.48% | 20.48% | 33.38% | 15.54% | 23.58% |
| Zoetis | 1.51% | 1.63% | 3.59% | -3.30% | -5.26% | -3.68% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Amneal | 14.44% | 280.56% | 137.97% | -34.76% | -34.76% | -34.76% |
| Zoetis | -13.42% | -2.05% | -2.11% | 242.11% | 405.06% | 405.06% |
Performance & Financial Health Analysis: Amneal vs Zoetis
| Metric | AMRX | ZTS |
|---|---|---|
| Market Information | ||
| Market Cap | $2.99B | $65.30B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 1,865,350 | 4,111,510 |
| 90 Day Avg. Volume | 1,528,157 | 3,459,870 |
| Last Close | $9.59 | $167.10 |
| 52 Week Range | $6.68 - $9.79 | $139.70 - $200.33 |
| % from 52W High | -2.04% | -16.59% |
| All-Time High | $24.48 (Aug 20, 2018) | $249.27 (Dec 27, 2021) |
| % from All-Time High | -60.83% | -32.96% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.03% | 0.04% |
| Quarterly Earnings Growth | 2.74% | 0.15% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.28% |
| Operating Margin (TTM) | 0.15% | 0.40% |
| Return on Equity (TTM) | 1.07% | 0.53% |
| Debt to Equity (MRQ) | -22.94 | 137.01 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-0.36 | $11.21 |
| Cash per Share (MRQ) | $0.24 | $3.28 |
| Operating Cash Flow (TTM) | $351.08M | $2.93B |
| Levered Free Cash Flow (TTM) | $333.75M | $2.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.11% |
| Last 12-Month Dividend | N/A | $1.86 |
Valuation & Enterprise Metrics Analysis: Amneal vs Zoetis
| Metric | AMRX | ZTS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 953.00 | 25.36 |
| Forward P/E | 13.42 | 23.24 |
| PEG Ratio | 3.81 | 23.24 |
| Price to Sales (TTM) | 1.05 | 6.96 |
| Price to Book (MRQ) | -26.76 | 13.14 |
| Market Capitalization | ||
| Market Capitalization | $2.99B | $65.30B |
| Enterprise Value | $5.57B | $70.67B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.95 | 7.53 |
| Enterprise to EBITDA | 8.90 | 17.91 |
| Risk & Other Metrics | ||
| Beta | 1.12 | 0.88 |
| Book Value per Share (MRQ) | $-0.36 | $11.21 |
Financial Statements Comparison: Amneal vs Zoetis
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AMRX | ZTS |
|---|---|---|
| Revenue/Sales | $695.42M | $2.22B |
| Cost of Goods Sold | $439.53M | $622.00M |
| Gross Profit | $255.89M | $1.60B |
| Research & Development | $41.81M | $157.00M |
| Operating Income (EBIT) | $100.92M | $846.00M |
| EBITDA | $161.60M | $991.00M |
| Pre-Tax Income | $37.49M | $810.00M |
| Income Tax | $12.87M | $179.00M |
| Net Income (Profit) | $24.62M | $631.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AMRX | ZTS |
|---|---|---|
| Cash & Equivalents | $59.19M | $1.72B |
| Total Current Assets | $1.51B | $5.88B |
| Total Current Liabilities | $1.08B | $3.39B |
| Long-Term Debt | $2.24B | $5.40B |
| Total Shareholders Equity | $-59.39M | $4.66B |
| Retained Earnings | $-594.87M | $12.38B |
| Property, Plant & Equipment | $522.75M | $6.36B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AMRX | ZTS |
|---|---|---|
| Operating Cash Flow | $-11.03M | $567.00M |
| Capital Expenditures | $-13.60M | N/A |
| Free Cash Flow | $-10.91M | $438.00M |
| Debt Repayment | $-235.53M | N/A |
| Common Stock Repurchase | N/A | $-443.00M |
Short Interest & Institutional Ownership Analysis
| Metric | AMRX | ZTS |
|---|---|---|
| Shares Short | 4.93M | 7.85M |
| Short Ratio | 3.55 | 2.67 |
| Short % of Float | 0.02% | 0.02% |
| Average Daily Volume (10 Day) | 1,865,350 | 4,111,510 |
| Average Daily Volume (90 Day) | 1,528,157 | 3,459,870 |
| Shares Outstanding | 309.88M | 448.47M |
| Float Shares | 168.50M | 442.37M |
| % Held by Insiders | 0.47% | 0.00% |
| % Held by Institutions | 0.46% | 0.98% |
Dividend Analysis & Yield Comparison: Amneal vs Zoetis
| Metric | AMRX | ZTS |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.86 |
| Last 12-Month Dividend Yield | N/A | 1.11% |
| 3-Year Avg Annual Dividend | N/A | $1.63 |
| 3-Year Avg Dividend Yield | N/A | 0.24% |
| 3-Year Total Dividends | N/A | $4.90 |
| Ex-Dividend Date | N/A | Apr 21, 2025 |